Hepatic manifestations of non-steroidal inflammatory bowel disease therapy

Inflammatory bowel disease(IBD) is composed of Crohn’s disease and ulcerative colitis and is manifested by both bowel-related and extraintestinal manifestations. Recently the number of therapeutic options available to treat IBD has dramatically increased, with each new medication having its own mech...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of hepatology Vol. 7; no. 27; pp. 2716 - 2728
Main Author Hirten, Robert
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 28.11.2015
Subjects
drug
Hepatotoxicity;Adverse
induced
reactions;Drug
Review
Inflammatory bowel disease
Drug induced liver injury
Adverse drug reactions
Hepatotoxicity
Crohn’s disease
Ulcerative colitis
Online AccessGet full text
ISSN1948-5182
1948-5182
DOI10.4254/wjh.v7.i27.2716

Cover

More Information
Summary:Inflammatory bowel disease(IBD) is composed of Crohn’s disease and ulcerative colitis and is manifested by both bowel-related and extraintestinal manifestations. Recently the number of therapeutic options available to treat IBD has dramatically increased, with each new medication having its own mechanism of action and side effect profile. A complete understanding of the hepatotoxicity of these medications is important in order to distinguish these complications from the hepatic manifestations of IBD. This review seeks to evaluate the hepatobiliary complications of non-steroid based IBD medications and aide providers in the recognition and management of these side-effects.
Bibliography:Robert Hirten;Keith Sultan;Ashby Thomas;David E Bernstein;Division of Gastroenterology, North Shore University Hospital--Long Island Jewish Medical Center
Hepatotoxicity;Adverse drug reactions;Drug induced
Inflammatory bowel disease(IBD) is composed of Crohn’s disease and ulcerative colitis and is manifested by both bowel-related and extraintestinal manifestations. Recently the number of therapeutic options available to treat IBD has dramatically increased, with each new medication having its own mechanism of action and side effect profile. A complete understanding of the hepatotoxicity of these medications is important in order to distinguish these complications from the hepatic manifestations of IBD. This review seeks to evaluate the hepatobiliary complications of non-steroid based IBD medications and aide providers in the recognition and management of these side-effects.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Author contributions: Hirten R, Sultan K and Bernstein DE contributed to conception and design; Hirten R, Sultan K and Thomas A contributed to drafting of the article; Hirten R, Sultan K, Thomas A and Bernstein DE contributed to critical revision of the article for important intellectual content; Hirten R, Sultan K, Thomas A and Bernstein DE contributed to final approval of the article.
Correspondence to: Dr. David E Bernstein, MD, Chief of Division of Hepatology, North Shore University Hospital-Long Island Jewish Medical Center, 300 Community Drive, Manhasset, NY 11030, United States. dbernste@nshs.edu
Telephone: +1-516-5624664 Fax: +1-516-5621688
ISSN:1948-5182
1948-5182
DOI:10.4254/wjh.v7.i27.2716